The Weight-Loss Drug Gold Rush Is Getting Larger
December 5, 2023

(Wall Street Journal) – More drug companies are racing to join what’s been a two-horse race to make blockbuster obesity drugs, snapping up smaller biotechs and vying for a market that could be worth tens of billions in less than a decade. Why it matters: GLP-1 agonists like Novo Nordisk’s Wegovy and Ozempic have soared in popularity despite high price tags, mixed insurance coverage and a number of unpleasant side effects. (Read More)